Multicenter observational study of chemotherapy-induced peripheral neuropathy prevention - Multicenter Observational Study of CIPN prevention

Kyoto Breast Cancer Research Network (KBCRN)0 个研究点目标入组 480 人开始时间: 2021年4月1日最近更新: 2024年9月2日

适应症

试验速览

暂无简介。

•1)Patients who have CTCAE more than grade1 neuropathy and/or skin disorders 2)Patients taking pregabalin, etc. to control neuropathic pain 3)active double cancer (except lesions corresponding to carcinoma in situ or intramucosal cancer that are judged to be cured by local treatment are not included in the double cancer). 4)active brain metastasis 5)Diabetes mellitus with peripheral neuropathy, infectious diseases (on limbs) that are judged to interfere with prevention, and other serious complications are observed. 6)History of severe drug hypersensitivity in therapeutically important drugs in this study 7)History of serious mental illness or under treatment 8)HBsAg positive and untreated 9)History of serious heart or respiratory illness 10)May be pregnant or pregnant 11)In addition, when the principal investigator or the research coordinator determines that the subject is inappropriate (specific example: signs of peripheral circulatory insufficiency such as Raynaud's phenomenon)

发起方

Kyoto Breast Cancer Research Network (KBCRN)